HK1126223A1 - Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration - Google Patents

Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Info

Publication number
HK1126223A1
HK1126223A1 HK09104433.8A HK09104433A HK1126223A1 HK 1126223 A1 HK1126223 A1 HK 1126223A1 HK 09104433 A HK09104433 A HK 09104433A HK 1126223 A1 HK1126223 A1 HK 1126223A1
Authority
HK
Hong Kong
Prior art keywords
methods
age
cfhr
macular degeneration
related macular
Prior art date
Application number
HK09104433.8A
Other languages
English (en)
Inventor
Gregory S S Hageman
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of HK1126223A1 publication Critical patent/HK1126223A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
HK09104433.8A 2006-07-13 2009-05-14 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration HK1126223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83101806P 2006-07-13 2006-07-13
US84007306P 2006-08-23 2006-08-23
PCT/US2007/073514 WO2008008986A2 (fr) 2006-07-13 2007-07-13 Procédés et réactifs pour le traitement et le diagnostic de troubles vasculaires et de la dégénérescence maculaire liée à l'age

Publications (1)

Publication Number Publication Date
HK1126223A1 true HK1126223A1 (en) 2009-08-28

Family

ID=38924245

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09104433.8A HK1126223A1 (en) 2006-07-13 2009-05-14 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
HK12109179.0A HK1168360A1 (en) 2006-07-13 2012-09-18 Methods and reagents for treatment of age-related macular degeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12109179.0A HK1168360A1 (en) 2006-07-13 2012-09-18 Methods and reagents for treatment of age-related macular degeneration

Country Status (12)

Country Link
US (4) US7867727B2 (fr)
EP (3) EP2479284B1 (fr)
JP (1) JP5431151B2 (fr)
AT (1) ATE551350T1 (fr)
AU (1) AU2007272335B2 (fr)
CA (1) CA2659392A1 (fr)
DK (1) DK2447275T3 (fr)
HK (2) HK1126223A1 (fr)
IL (1) IL196319A0 (fr)
NZ (1) NZ574046A (fr)
SG (1) SG173371A1 (fr)
WO (1) WO2008008986A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302076B1 (fr) * 2005-02-14 2014-11-12 University of Iowa Research Foundation Procédés et réactifs pour le traitement et le diagnostic de la dégénération maculaire liée à l'âge
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
JP2009544317A (ja) * 2006-07-26 2009-12-17 イェール ユニバーシティー 加齢性黄斑変性の診断および治療
WO2009059321A2 (fr) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Analyse de lieu de rca pour estimer la sensibilité à l'amd et au mpgnii
JP2011510297A (ja) * 2008-01-18 2011-03-31 バトリックス・メディカル・インコーポレイテッド 動脈瘤のための診断バイオマーカー
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
CA2768237A1 (fr) * 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Methode de traitement
WO2011017229A2 (fr) * 2009-08-06 2011-02-10 Tufts - New England Medical Center Composants de complément plasmatique en tant que marqueurs d'expression pour la dégénérescence maculaire liée à l'âge et les phénotypes afférents
US20120241321A1 (en) * 2009-09-14 2012-09-27 Harald Mischak Polypeptide marker for diagnosing and assessing vascular diseases
JP5706612B2 (ja) * 2009-12-28 2015-04-22 学校法人 埼玉医科大学 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット
WO2012051462A2 (fr) * 2010-10-14 2012-04-19 Sequenom, Inc. Variations du nombre de copies du facteur h du complément dans le locus rca
WO2012112955A2 (fr) 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Procédés d'identification de sujets présentant un risque génétique de développer une néphropathie à iga
SG194235A1 (en) * 2011-04-29 2013-12-30 Univ Utah Res Found Methods of predicting the development of complement-mediated disease
JP2013064616A (ja) * 2011-09-15 2013-04-11 Osaka Univ 高度動脈硬化を発症している可能性を検出する方法およびその利用
WO2013150132A2 (fr) * 2012-04-05 2013-10-10 Mosaiques Diagnostics And Therapeutics Ag Marqueurs polypeptidiques pour diagnostiquer et évaluer des accidents vasculaires cérébraux
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
WO2014131714A1 (fr) * 2013-02-26 2014-09-04 Roche Diagnostics Gmbh Agents, kits et méthodes pour la détection de la protéine 1 associée au facteur h du complément
WO2014169294A1 (fr) 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Mutations dans dstyk provoquant des malformations dominantes dans les voies urinaires
WO2014194213A1 (fr) * 2013-05-30 2014-12-04 University Of Iowa Research Foundation Protéines de complément spécifiques et efficacité d'une thérapie par les anticorps
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
CA3009553A1 (fr) 2015-12-23 2017-06-29 Centre National De La Recherche Scientifique Agents inhibant la liaison de cfh a cd11b/cd18 et leurs utilisations
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
WO2019215330A1 (fr) * 2018-05-10 2019-11-14 The University Of Manchester Méthodes d'évaluation de la dégénérescence maculaire
DE102018120016B4 (de) * 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
US20220146530A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof
JP2022526429A (ja) 2019-04-10 2022-05-24 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション Ａｍｄの処置のためのｈｔｒａ１調節
US20210123076A1 (en) * 2019-10-22 2021-04-29 Applied Genetic Technologies Corporation Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders
WO2022058447A1 (fr) * 2020-09-16 2022-03-24 The University Of Manchester Test du « complémentome »

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
AU632494B2 (en) 1988-05-20 1993-01-07 F. Hoffmann-La Roche Ag Immobilized sequence-specific probes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP1413587A2 (fr) 1991-05-03 2004-04-28 Washington University Régulateur modifié du système de complément
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0655090B1 (fr) 1992-04-27 2000-12-27 The Trustees Of Dartmouth College Detection de sequences geniques dans des liquides biologiques
AU5961994A (en) 1993-01-22 1994-08-15 University Research Corporation Localization of therapeutic agents
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
ATE343792T1 (de) 1999-02-19 2006-11-15 Univ Iowa Res Found Diagnostika und therapeutika für maculare degeneration
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CA2404890C (fr) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Mediateurs d'interference arn specifiques de sequences arn
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
ES2215494T5 (es) 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US7255858B2 (en) 2001-08-10 2007-08-14 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
EP1836312B1 (fr) * 2004-11-18 2011-10-12 Yale University Methodes et preparations pour le diagnostic de la la dégénération maculaire liée à l'âge
EP2302076B1 (fr) 2005-02-14 2014-11-12 University of Iowa Research Foundation Procédés et réactifs pour le traitement et le diagnostic de la dégénération maculaire liée à l'âge
US7695909B2 (en) 2005-06-08 2010-04-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
WO2007044897A1 (fr) 2005-10-11 2007-04-19 Yale University Genes associes a la degenerescence maculaire
EP1941061A1 (fr) 2005-11-02 2008-07-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Procédé élaboré pour la reconnaissance et le test de la dégénérescence maculaire liée à l'âge (dmla)
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration

Also Published As

Publication number Publication date
US20080152659A1 (en) 2008-06-26
IL196319A0 (en) 2009-09-22
DK2447275T3 (en) 2015-06-29
US20180371547A1 (en) 2018-12-27
US20150050646A1 (en) 2015-02-19
EP2479284B1 (fr) 2017-09-20
US7867727B2 (en) 2011-01-11
AU2007272335A1 (en) 2008-01-17
WO2008008986A2 (fr) 2008-01-17
ATE551350T1 (de) 2012-04-15
HK1168360A1 (en) 2012-12-28
EP2046807A4 (fr) 2009-10-28
EP2479284A2 (fr) 2012-07-25
EP2046807A2 (fr) 2009-04-15
EP2479284A3 (fr) 2012-08-08
EP2046807B1 (fr) 2012-03-28
EP2447275A1 (fr) 2012-05-02
SG173371A1 (en) 2011-08-29
AU2007272335B2 (en) 2014-03-27
JP5431151B2 (ja) 2014-03-05
NZ574046A (en) 2012-09-28
WO2008008986A3 (fr) 2008-10-23
EP2447275B1 (fr) 2015-04-01
US20120040884A1 (en) 2012-02-16
JP2009544280A (ja) 2009-12-17
CA2659392A1 (fr) 2008-01-17

Similar Documents

Publication Publication Date Title
HK1126223A1 (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
WO2009059318A3 (fr) Gènes et polymorphismes associés à l'amd
Gregson et al. A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date
WO2006062716A3 (fr) Methodes et preparations pour le traitement de troubles oculaires
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
WO2008008433A3 (fr) Acylanilides substitués et procédés d'utilisation de ceux-ci
WO2008052798A3 (fr) Fgfr4 favorise la résistance des cellules cancéreuses en réponse aux médicaments chimiothérapiques
WO2005020972A3 (fr) Polytherapie pour le traitement de troubles neovasculaires oculaires
NZ595305A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2007022506A3 (fr) Méthodes et préparations pour le traitement d'une maladie neurologique
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2008137762A3 (fr) Procédés de diagnostic et de traitement de la maladie de crohn
WO2003013535A3 (fr) Moyens et methodes de traitement ameliore du cancer fondes sur mdr1
MX2012013613A (es) Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.
WO2008074329A3 (fr) Modulation de l'activité de pro-neurotrophines
WO2004009610A3 (fr) Utilisation de composes nucleosidiques pour la suppression non-sens et le traitement de maladies genetiques
WO2008143774A3 (fr) Procédés et compositions permettant de déterminer l'hétérozygocité snp dans le cadre d'un diagnostic et d'une thérapie allèle-spécifiques
WO2006029142A3 (fr) Methodes et systemes de traitement de l'asthme et d'autres maladies respiratoires
WO2005110056A3 (fr) Compositions contenant des recepteurs d'addl, compositions et methodes associees
NO20055884L (no) Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt
WO2006078853A3 (fr) Proteine d'interaction avec la thioredoxine (txnip) en tant que regulateur de la fonction vasculaire
WO2006131512A3 (fr) Agents antithrombiques
WO2004006856A3 (fr) Sequestration ou elimination du fer pour reduire la neurodegenerescence ou la progression de la maladie de parkinson
WO2006076695A3 (fr) Criblage genetique destine a ameliorer le traitement de patients diagnostiques comme depressifs

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230713